← Leaderboards
Karin Marie Hardiman
University Of Alabama At Birmingham
$2,227,249
Attributed
$2,227,249
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $414.7K · FY2016–25$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,227,249 · 2
By mechanism
R01$1,527,409 · 1
K08$699,840 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Courtney Marie Peterson$4,655,471
- Karlene K Ball$19,184,966
- Eben L Rosenthal$10,844,750
- Awalpreet Singh Chadha$529,966
- Victor William Mark$1,245,173
Others in their field
Top investigators on “Treatment Response”
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$249,783,490
- David Heimbrook · Leidos Biomedical Research, Inc.$226,464,484
- Jeffrey P Krischer · University Of South Florida$179,054,592
- Lawrence Corey · Fred Hutchinson Cancer Center$168,164,123
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
Research focus
Treatment ResponseNeoplasm MetastasisResponseAftercareCessation Of LifeRectal CancerPrimary NeoplasmResistanceTherapy ResistantTumorTissuesSamplingFutureCancer EtiologyMalignant NeoplasmsFunctional GainApoptoticApoptosisCellsCell SurfaceGastrointestinalChargeAdenocarcinomaChemoradiation
Grant awards (8)
A novel, transferable sialylation-mediated mechanism of chemoradioresistance in GI cancer$366,789
R01 · FY2025 · CA · contact PI
A novel, transferable sialylation-mediated mechanism of chemoradioresistance in GI cancer$367,186
R01 · FY2024 · CA · contact PI
A novel, transferable sialylation-mediated mechanism of chemoradioresistance in GI cancer$378,779
R01 · FY2023 · CA · contact PI
A novel, transferable sialylation-mediated mechanism of chemoradioresistance in GI cancer$414,655
R01 · FY2022 · CA · contact PI
Intra-tumor Heterogeneity in Colorectal Cancer Progression and Treatment Response$174,960
K08 · FY2019 · CA · contact PI
Intra-tumor Heterogeneity in Colorectal Cancer Progression and Treatment Response$174,960
K08 · FY2018 · CA · contact PI
Intra-tumor Heterogeneity in Colorectal Cancer Progression and Treatment Response$174,960
K08 · FY2017 · CA · contact PI
Intra-tumor Heterogeneity in Colorectal Cancer Progression and Treatment Response$174,960
K08 · FY2016 · CA · contact PI